A genome sequence is a fixed record, but variant interpretation keeps changing as new evidence, databases and tools appear. A variant labelled uncertain today may be reclassified later, and a gene-disease link that did not exist when your report was written may exist now. Reanalysis means re-examining the same data with current knowledge.
There is no universal schedule. A sensible habit is to revisit your results when something changes in your health or family, and every couple of years otherwise.
Fixed data, moving knowledge
When a lab sequences your genome, it produces a record of your DNA that does not change. What does change is the meaning attached to what is in it. A report is a snapshot of the scientific evidence on the day it was written.
The American College of Medical Genetics and Genomics addressed this in a 2019 statement on reevaluating genomic variants. It notes that variant classification is ongoing, because the evidence base shifts as new variant data, computational tools and functional studies appear, and that previously classified variants will frequently benefit from periodic reevaluation. It also names three other reasons: patients' symptoms can develop or change after testing, gene-disease associations expand over time, and improved bioinformatics pipelines may reveal variants that were missed earlier.
What can change in a report
- Uncertain variants get answers. A variant of uncertain significance can move toward pathogenic or benign as evidence accumulates. Our guide to variants of uncertain significance explains how.
- Classifications can move in either direction. New evidence can strengthen or weaken a variant's classification. ACMG advises prioritising variants currently classed as uncertain or likely pathogenic for review.
- New gene-disease links. A gene with no known link to a condition may gain one, which can make a previously irrelevant variant relevant.
- Better detection of hard variants. Tools improve at finding larger changes, such as those described in our structural variants guide.
- Better reference data. Improved reference genomes can expose regions that were previously unreadable. See the T2T reference genome explainer.
- Prescribing guidance. Pharmacogenomic recommendations get updated, as we describe in our pharmacogenomic interpretation guide.
Reanalysis is not a promise. It can leave your report unchanged. Many people who reanalyse find nothing new, and a different result is not guaranteed. The ACMG statement describes it as helping unsolved cases as knowledge grows, not as a guarantee.
Reanalysis versus retesting
These are different tools.
| Reanalysis | Retesting | |
|---|---|---|
| What happens | Same sequence data, re-examined with updated knowledge and tools | New sample, new sequencing, possibly a different method |
| Best when | Knowledge or tools have changed, and the data is good | The original data had gaps, or a newer method sees more |
| Cost and effort | Usually lower, but availability and pricing vary | Usually higher |
ACMG notes that newer methods, such as genome sequencing after a nondiagnostic exome, may be preferable to reanalysis, depending on time elapsed, technology changes and new clinical information. If your original test was an exome or a lower-depth genome, see whole genome versus whole exome sequencing and what 30x coverage means to judge whether reanalysis can reach what you need.
When to ask for reanalysis
- New symptoms or diagnoses in you, which may make an old finding relevant.
- A new diagnosis or genetic result in the family.
- An uncertain variant in a gene that now seems relevant to your situation.
- A change in clinical guidance or a new test for your condition.
- A few years have passed and you have not reviewed anything. This is our suggested habit rather than a formal guideline. The only specific interval in the ACMG statement is a laboratory policy review at least every two years, which is a lab-side rule rather than a patient schedule.
How to get it done
- Ask your provider. Find out whether the company re-runs customer files against updated databases, how often, and whether it is free or a paid add-on.
- Ask your clinician. If your test was ordered through a clinic or lab, a clinician can request reanalysis, usually with updated clinical information. Laboratories vary in how they handle it, and the ACMG statement notes that reanalysis demands time and money and that reimbursement is inadequate, so ask about cost.
- Check public databases yourself, carefully. If you hold a VCF file, you can compare variants with public resources, but a variant looking alarming in an automated tool is often a false alarm. Read how to analyze raw genome data and why raw data reports throw false alarms first.
- Use a counselor for anything that matters. See do you need a genetic counselor.
What reanalysis cannot do
- It cannot create missing data. If a region was poorly covered, it stays poorly covered.
- It cannot invent evidence. A rare variant with no supporting research stays uncertain.
- It cannot replace testing for specific suspected conditions that need a targeted method.
- It cannot guarantee a diagnosis.
Keep your own data in a usable form
Reanalysis depends on having the files. Download your raw data when it is available, and note which reference genome build it uses, since mismatches break tools (see GRCh37 vs GRCh38). Keep a backup you control, as we discuss in how to store and back up your genome files. Our overview of FASTQ, BAM and VCF files explains which ones matter. Newer approaches that use AI to interpret variants, covered in our AI variant interpretation article, will likely make reanalysis cheaper over time.
Bottom line
A genome is a lasting asset only if you can still use it. Keep the files, note what the original report said and when, and set a reminder to revisit it when your life or the science moves on. If you are still choosing a provider, ask about updates in our pre-purchase questions.
Reanalysis starts with owning your data
A genome you can download is a genome you can have re-examined later, by a clinician, a counselor or a new tool. Dante Labs delivers your raw data, so the file is still useful in ten years. Check its current update and reanalysis policy on its own pages before you buy.
Compare Dante Labs WGS → Code GENOME — 10% offAffiliate link. Consumer sequencing is not a clinical diagnostic. Confirm findings through your doctor.
Common questions
Does my DNA sequence change over time?
No. Your sequence data is fixed. What changes is the scientific knowledge used to interpret it, so a report written years ago can become outdated even though the underlying data has not.
What is genome reanalysis?
It means re-examining the same sequence data using current databases, classifications and software. It is different from retesting, which uses a new sample and new sequencing.
How often should I reanalyse my genome?
There is no universal schedule. A reasonable habit is to review when your health or family history changes and every couple of years otherwise. The ACMG statement mentions lab policy reviews at least every two years, which is a laboratory practice rather than a patient rule.
Can reanalysis change an uncertain result?
Yes, it can. Variants of uncertain significance can be reclassified as new evidence appears, though many stay uncertain and some move toward benign rather than pathogenic.
Is reanalysis the same as getting a new genome test?
No. Reanalysis uses your existing data. A new test makes sense when the original data had gaps or a newer method can see more, for example genome sequencing after a nondiagnostic exome.
Sources and verification
Verified October 2026 against the ACMG statement on reevaluation (2019), which is the primary source for the reasons for reanalysis, priority and the two-year laboratory policy review. We did not state diagnostic-yield figures because we did not verify any. Consumer provider update policies were not verified.
Medical disclaimer. GenomeTesting.org publishes educational content about genetics and consumer genomic testing. Nothing here is medical advice, a diagnosis, or a substitute for care from a qualified clinician or genetic counsellor. Decisions about testing, treatment, or interpreting your own results should be made with a healthcare professional who can see your full history.
Affiliate disclosure. Some links on this page are affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes which products we recommend or what we say about them.